The observation that ZDHHC7 and ZDHHC12 have opposing and sequential regulatory effects on the NLRP3 inflammasome process also suggests that it is beneficial to have ZDHHC7-specific inhibitors to block the initiation of NLRP3 activation for treating inflammasome hyperactivation in human autoimmune diseases. Here, NLRP3 is linked to autoimmune disease.